Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Insulin for Neurotrophic Keratopathy
NCT05321251Phase 3Withdrawn
- Sponsor
- University of Alberta
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human insulin in neurotrophic keratopathy (NK) (2 arms), sponsored by University of Alberta. Primary endpoint: Time to re-epithelialization of neurotrophic ulcer at 3 months. Planned start Jun 2022; status: withdrawn.
02
Drugs
human insulin
03
Conditions
neurotrophic keratopathy (NK)
Beyond the preview
Go deeper on NCT05321251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321251.